Pathophysiologic Targets of Allergic Asthma

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Defining Allergic Asthma

FDA-Approved Agents for Severe Allergic Asthma Not a One-Size-Fits-All Therapy

Clarifying the Allergic Asthma Phenotype

Pathophysiology of Allergic Asthma

Asthma: A Heterogenous Disease With Multiple Phenotypes

Drivers of Allergic Asthma

IL-5

IL-4

IL-13

Inflammatory Mechanisms of Allergic Asthma

Mast Cells

Concluding Remarks

Therapeutic Targets for Severe Allergic Asthma

FDA-Approved Agents for Severe Allergic Asthma and Their Targets

Clinical Implications of TH2 Biomarkers

Eosinophil Levels Vary Over Time in Patients With Severe Asthma

Baseline Clinical Factors and Blood Eosinophil Count Can Help Identify Patients Who Are Potentially Responsive to Benralizumab

Liberty Asthma QUEST: Phase 3 Study of Efficacy of Dupilumab on Inflammatory Biomarkers of Asthma in Patients With/Without Allergic Rhinitis

Liberty Asthma QUEST: Phase 3 Study of Efficacy of Dupilumab on Inflammatory Biomarkers of Asthma in Patients With/Without Chronic Rhinosinusitis/Nasal Polyps

Baseline Blood Eosinophil Levels and/or Clinical Markers of Asthma Severity Predict Response to Omalizumab in Patients With Allergic Asthma

Concluding Remarks

Clinical Impact of Targeting Allergic Asthma

Severe Allergic Asthma: Links Between Exacerbations and Outcomes

Preseasonal Treatment With Omalizumab or ICS Boost in Children to Prevent Asthma Exacerbation in the Fall Season

Omalizumab in Pediatric Patients With Allergic Asthma and Allergic Rhinitis

PROSPERO: Outcomes After Initiation of Omalizumab in a Real-World Setting

PROSPERO: What Did We Learn?

Comorbidities in Patients With TH2-Asthma Substantially Increase Risk of Asthma Exacerbations

Dupilumab for Adults With Concurrent Asthma, Atopic Dermatitis, and Sinonasal Conditions

Liberty Asthma QUEST: Dupilumab for Asthma With Allergic Asthma

Mepolizumab for Asthma With Allergic Rhinitis, Chronic Rhinosinusitis, and/or Nasal Polyps

Concluding Remarks

Abbreviations

Abbreviations (cont)

Abbreviations (cont)